X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (17766) 17766
Newsletter (1374) 1374
Newspaper Article (211) 211
Magazine Article (95) 95
Book Chapter (8) 8
Dissertation (8) 8
Reference (5) 5
Book / eBook (4) 4
Conference Proceeding (2) 2
Publication (2) 2
Streaming Video (1) 1
Transcript (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
niacinamide (9102) 9102
humans (8361) 8361
animals (6795) 6795
niacinamide - analogs & derivatives (6237) 6237
male (5487) 5487
female (3967) 3967
niacinamide - pharmacology (3659) 3659
rats (2653) 2653
middle aged (2328) 2328
niacinamide - therapeutic use (2307) 2307
mice (2245) 2245
oncology (2151) 2151
analysis (2133) 2133
sorafenib (2098) 2098
research (1938) 1938
phosphates (1874) 1874
aged (1858) 1858
phenylurea compounds (1826) 1826
cancer (1802) 1802
adult (1796) 1796
biochemistry & molecular biology (1736) 1736
antineoplastic agents - therapeutic use (1641) 1641
nicotinamide (1622) 1622
pharmacology & pharmacy (1580) 1580
purines (1473) 1473
enzymes (1456) 1456
niacinamide - administration & dosage (1451) 1451
physiological aspects (1376) 1376
treatment outcome (1301) 1301
liver neoplasms - drug therapy (1200) 1200
carcinoma, hepatocellular - drug therapy (1157) 1157
phenylurea compounds - therapeutic use (1131) 1131
oxidative stress (1127) 1127
niacinamide - metabolism (1126) 1126
nad (1093) 1093
apoptosis (1072) 1072
cell line, tumor (1035) 1035
pyridines - therapeutic use (1015) 1015
expression (991) 991
benzenesulfonates - therapeutic use (970) 970
cell biology (913) 913
care and treatment (891) 891
oxidases (885) 885
time factors (864) 864
nad - metabolism (826) 826
dose-response relationship, drug (818) 818
metabolism (803) 803
liver neoplasms - pathology (779) 779
hepatocellular carcinoma (768) 768
antineoplastic agents (764) 764
antineoplastic agents - pharmacology (761) 761
proteins (757) 757
kinetics (755) 755
niacin (743) 743
carcinoma, renal cell - drug therapy (739) 739
carcinoma, hepatocellular - pathology (738) 738
kidney neoplasms - drug therapy (726) 726
antimitotic agents (712) 712
health aspects (708) 708
protein kinase inhibitors - therapeutic use (705) 705
antineoplastic agents - adverse effects (702) 702
niacinamide - adverse effects (702) 702
adenine (693) 693
niacinamide - chemistry (689) 689
phenylurea compounds - administration & dosage (680) 680
phenylurea compounds - pharmacology (672) 672
aged, 80 and over (668) 668
activation (665) 665
cells (653) 653
apoptosis - drug effects (643) 643
neurosciences (643) 643
cells, cultured (640) 640
glucose (634) 634
liver (632) 632
in vitro techniques (630) 630
superoxide (627) 627
nitric oxide (609) 609
pyridines - pharmacology (588) 588
chemotherapy (573) 573
antioxidants (571) 571
nicorandil (564) 564
inhibition (563) 563
gene expression (560) 560
rats, wistar (555) 555
cell proliferation - drug effects (547) 547
therapy (547) 547
survival (543) 543
liver cancer (542) 542
biophysics (534) 534
disease models, animal (531) 531
coenzymes (529) 529
phenylurea compounds - adverse effects (522) 522
endocrinology & metabolism (520) 520
prognosis (518) 518
oxidation-reduction (514) 514
tumors (512) 512
antineoplastic agents - administration & dosage (503) 503
gastroenterology & hepatology (502) 502
pyridines - adverse effects (485) 485
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (18015) 18015
Russian (582) 582
German (324) 324
Japanese (317) 317
Italian (243) 243
French (198) 198
Chinese (118) 118
Ukrainian (51) 51
Polish (41) 41
Spanish (41) 41
Portuguese (17) 17
Czech (15) 15
Hungarian (12) 12
Dutch (9) 9
Korean (7) 7
Romanian (7) 7
Turkish (6) 6
Bulgarian (5) 5
Danish (5) 5
Norwegian (3) 3
Slovak (3) 3
Swedish (3) 3
Afrikaans (2) 2
Armenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Equine Veterinary Journal, ISSN 0425-1644, 06/2014, Volume 46, Issue S46, pp. 27 - 27
Introduction There are no published studies that characterize the different myofiber types of Mangalarga (ML) horses and hybrids. This study aimed to... 
Niacinamide
Journal Article
Cell metabolism, ISSN 1550-4131, 2016, Volume 24, Issue 2, pp. 269 - 282
Journal Article
The Journal of pharmacology and experimental therapeutics, ISSN 0022-3565, 03/2008, Volume 324, Issue 3, pp. 883 - 893
The role of NAD(+) metabolism in health and disease is of increased interest as the use of niacin (nicotinic acid) has emerged as a major therapy for treatment... 
Niacinamide - analogs & derivatives | NAD - genetics | Niacinamide - metabolism | Humans | NAD - physiology | Niacinamide - therapeutic use | Signal Transduction - genetics | Niacinamide - physiology | Animals | Signal Transduction - drug effects | Niacinamide - genetics | Signal Transduction - physiology | NAD - metabolism
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2009, Volume 27, Issue 23, pp. 3794 - 3801
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2015, Volume 33, Issue 2, pp. 172 - 179
Purpose This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma... 
ANGIOGENESIS | ONCOLOGY | PATHWAY | SUNITINIB | ABT-869 | RISK | BRIVANIB | INHIBITOR | CANCER | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Hand-Foot Syndrome - etiology | Indazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Liver Neoplasms - etiology | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Hypertension - chemically induced | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Liver Neoplasms - pathology | Carcinoma, Hepatocellular - etiology | Odds Ratio | Drug Administration Schedule | Risk Factors | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Niacinamide - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Phenylurea Compounds - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Sorafenib | Carcinoma, Hepatocellular - pathology | Aged | Indazoles - adverse effects | Indazoles - therapeutic use | Bone3 | ORIGINAL REPORTS | Bios3
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1344 - 1354
Summary Background There is no standard of care for adjuvant therapy for patients with hepatocellular carcinoma. This trial was designed to assess the efficacy... 
Hematology, Oncology and Palliative Medicine | CLINICAL-PRACTICE GUIDELINES | DIAGNOSIS | LIVER-TRANSPLANTATION | RISK-FACTORS | THERAPY | MANAGEMENT | ONCOLOGY | SAFETY | PREVENTION | RECURRENCE | Catheter Ablation - mortality | South America | Carcinoma, Hepatocellular - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Hepatectomy - mortality | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | North America | Young Adult | Carcinoma, Hepatocellular - drug therapy | Time Factors | Aged, 80 and over | Liver Neoplasms - pathology | Catheter Ablation - adverse effects | Chemotherapy, Adjuvant | Europe | Risk Factors | Niacinamide - adverse effects | Niacinamide - therapeutic use | Disease Progression | New Zealand | Protein Kinase Inhibitors - administration & dosage | Intention to Treat Analysis | Niacinamide - analogs & derivatives | Liver Neoplasms - mortality | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Adult | Female | Double-Blind Method | Hepatectomy - adverse effects | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Neoplasm Recurrence, Local | Phenylurea Compounds - therapeutic use | Carcinoma, Hepatocellular - surgery | Liver Neoplasms - surgery | Treatment Outcome | Niacinamide - administration & dosage | Disease-Free Survival | Phenylurea Compounds - administration & dosage | Asia | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Hepatocellular - pathology | Aged | Australia | Antimitotic agents | Liver cancer | Medical colleges | Surgery | Liver | Clinical trials | Hepatoma | Antineoplastic agents
Journal Article
Journal of hepatology, ISSN 0168-8278, 2012, Volume 57, Issue 4, pp. 821 - 829
Background & Aims The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall... 
Gastroenterology and Hepatology | Subset analyses | Time to progression | Hepatocellular carcinoma | Disease control rate | Overall survival | Sorafenib | SURVIVAL | DESIGN | MANAGEMENT | PROGNOSIS | RISK | NATURAL-HISTORY | CIRRHOSIS | STAGING SYSTEMS | CLINICAL-TRIALS | GASTROENTEROLOGY & HEPATOLOGY | EPIDEMIOLOGY | Niacinamide - analogs & derivatives | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Fatigue - chemically induced | Liver Neoplasms - therapy | Hand-Foot Syndrome - etiology | Hepatitis C, Chronic - complications | Diarrhea - chemically induced | Liver Neoplasms - etiology | Carcinoma, Hepatocellular - drug therapy | Time Factors | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Female | Liver Neoplasms - pathology | Carcinoma, Hepatocellular - etiology | Alcoholism - complications | Severity of Illness Index | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Niacinamide - adverse effects | Proportional Hazards Models | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Tumor Burden | Disease Progression | Hepatitis B, Chronic - complications | Carcinoma, Hepatocellular - pathology | Aged | Carcinoma, Hepatocellular - therapy | Neoplasm Staging | Antimitotic agents | Medical colleges | Liver cancer | Care and treatment | Analysis | Clinical trials | Product development | Hepatoma | Antineoplastic agents
Journal Article
Cell metabolism, ISSN 1550-4131, 10/2016, Volume 24, Issue 4, p. 526
In this issue, Fang et al. (2016) show that both the DNA repair defect and mitochondrial dysfunction in ATM.sup.-/- cells or mice are mitigated by the... 
Niacinamide
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2014, Volume 384, Issue 9940, pp. 319 - 328
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 07/2014, Volume 312, Issue 1, pp. 57 - 67
Journal Article
Journal Article